NASDAQ
PGEN

Precigen Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Precigen Inc Stock Price

Vitals

Today's Low:
$1.49
Today's High:
$1.6
Open Price:
$1.6
52W Low:
$0.81
52W High:
$2.89
Prev. Close:
$1.59
Volume:
1638667

Company Statistics

Market Cap.:
$462.42 million
Book Value:
0.651
Revenue TTM:
$22.10 million
Operating Margin TTM:
-334.83%
Gross Profit TTM:
$20.57 million
Profit Margin:
100.21%
Return on Assets TTM:
-17.5%
Return on Equity TTM:
-65.69%

Company Profile

Precigen Inc had its IPO on 2013-08-08 under the ticker symbol PGEN.

The company operates in the Healthcare sector and Biotechnology industry. Precigen Inc has a staff strength of 209 employees.

Stock update

Shares of Precigen Inc opened at $1.6 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.49 - $1.6, and closed at $1.52.

This is a -4.4% slip from the previous day's closing price.

A total volume of 1,638,667 shares were traded at the close of the day’s session.

In the last one week, shares of Precigen Inc have slipped by -16.02%.

Precigen Inc's Key Ratios

Precigen Inc has a market cap of $462.42 million, indicating a price to book ratio of 2.2782 and a price to sales ratio of 2.8823.

In the last 12-months Precigen Inc’s revenue was $22.10 million with a gross profit of $20.57 million and an EBITDA of $-66357000. The EBITDA ratio measures Precigen Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Precigen Inc’s operating margin was -334.83% while its return on assets stood at -17.5% with a return of equity of -65.69%.

In Q2, Precigen Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 39.3%.

Precigen Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Precigen Inc’s profitability.

Precigen Inc stock is trading at a EV to sales ratio of 2.9082 and a EV to EBITDA ratio of -7.3359. Its price to sales ratio in the trailing 12-months stood at 2.8823.

Precigen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$207.53 million
Total Liabilities
$30.77 million
Operating Cash Flow
$23.50 million
Capital Expenditure
$101000
Dividend Payout Ratio
0%

Precigen Inc ended 2024 with $207.53 million in total assets and $0 in total liabilities. Its intangible assets were valued at $207.53 million while shareholder equity stood at $166.21 million.

Precigen Inc ended 2024 with $2.18 million in deferred long-term liabilities, $30.77 million in other current liabilities, in common stock, $-1911620000.00 in retained earnings and $36.97 million in goodwill. Its cash balance stood at $16.55 million and cash and short-term investments were $88.43 million. The company’s total short-term debt was $1,421,000 while long-term debt stood at $0.

Precigen Inc’s total current assets stands at $105.63 million while long-term investments were $7.13 million and short-term investments were $71.89 million. Its net receivables were $14.41 million compared to accounts payable of $2.51 million and inventory worth $0.

In 2024, Precigen Inc's operating cash flow was $23.50 million while its capital expenditure stood at $101000.

Comparatively, Precigen Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.52
52-Week High
$2.89
52-Week Low
$0.81
Analyst Target Price
$9.5

Precigen Inc stock is currently trading at $1.52 per share. It touched a 52-week high of $2.89 and a 52-week low of $2.89. Analysts tracking the stock have a 12-month average target price of $9.5.

Its 50-day moving average was $1.42 and 200-day moving average was $1.38 The short ratio stood at 5.09 indicating a short percent outstanding of 0%.

Around 1006.6% of the company’s stock are held by insiders while 6242.5% are held by institutions.

Frequently Asked Questions About Precigen Inc

The stock symbol (also called stock or share ticker) of Precigen Inc is PGEN

The IPO of Precigen Inc took place on 2013-08-08

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$27.55
0.94
+3.53%
$18.95
-0.05
-0.26%
Sika AG ADR (SXYAY)
$26.61
-0.63
-2.31%
Oberoi Realty Limited (OBEROIRLTY)
$1139.8
-56.55
-4.73%
Sharda Cropchem Ltd (SHARDACROP)
$441.55
-11.4
-2.52%
Rane Holdings Limited (RANEHOLDIN)
$1093.7
-35.3
-3.13%
$1.8
-0.02
-0.83%
$6.17
-0.06
-0.96%
$499.3
-25.55
-4.87%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Address

20374 Seneca Meadows Parkway, Germantown, MD, United States, 20876